Best Neurology Companies in Denmark
The 37 best Neurology companies in Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NMD Pharma.
- Neurology Market Expected to Witness Sustained Growth
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in Denmark
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | NMD Pharma Developper of Ion-channel targeted drugs for treating neuromuscular synaptic disorders | $174M | 34 mo ago | 26 | — | Series B | 165 patents Small‑molecule therapeutics targeting chloride channels for neuromuscular diseases | — |
| 2 | Muna Therapeutics Developer of small-molecule therapeutics for neurodegenerative diseases | $102M | 47 mo ago | 16 | Rita Balice-Gordon CEO | Series B | 35 patents Modulating TREM2 and Kv1.3 ion channels for neuroinflammation and immune‑mediated disease therapy | — |
| 3 | Egalet Developer of therapeutics for pain management | $71M | 90 mo ago | 1 | — | Public | 84 patents Abuse‑deterrent controlled‑release pharmaceutical formulations and delivery systems. | — |
| 4 | Hoba Therapeutics Developer of therapeutics for the treatment of neuropathic pain and hearing disorders | $27M | 33 mo ago | 3 | Kenneth Petersen Founder | Series A | 22 patents Analgesic compounds for nociceptive and chemotherapy‑induced neuropathic pain treatment | — |
| 5 | NEUmiRNA Developer of RNA therapeutics for the treatment of neurological disorders | $21M | 20 mo ago | 3 | — | Series A | — | — |
| 6 | NsGene Drug delivery systems and therapeutics for CNS diseases. | $5M | 115 mo ago | — | Teit E Johansen CEO | Deadpooled | 188 patents Pain relief therapeutics via growth factor and encapsulated cell delivery platforms | — |
| 7 | RE5 ApS Developer of medical device for the treatment of neurological diseases | $3M | 188 mo ago | 1 | Peter Schøller Larsen Chairman & CEO & Director | Early Stage | — | — |
| 8 | OptoCeutics Provider of solutions for treating and diagnosing neurological disease | $3M | 70 mo ago | 10 10 → 15 (+50%) | Jes Broeng Co-Founder | Seed | — | — |
| 9 | Contera Pharma Developer of new innovative drugs for the treatment of movement disorders | $3M | 86 mo ago | 13 13 → 24 (+85%) | Thomas Sager CEO | Acquired | 95 patents Antisense oligonucleotide therapeutics and timed-release drug delivery for CNS disorders | — |
| 10 | Avilex Pharma Developer of neuroprotectants for multiple Indications | $2M | 135 mo ago | 2 | Kristian Stromgaard Co-Founder & CEO | Seed | — | — |
| 11 | Rehaler Provider of a medical device for the treatment of migraine | $2M | 39 mo ago | — | Henrik Olsen CEO | Funding Raised | — | — |
| 12 | Vesper Bio Developer of small molecule therapies to treat various diseases | $873K | 31 mo ago | 1 | Mads Kjolby Co-Founder | Funding Raised | 28 patents Therapeutics targeting sortilin protein for metabolic and neurodegenerative disease treatment | — |
| 13 | Manuxa Developer of Physical aids for gripping for individuals with functional impairments | $621K | 143 mo ago | 1 | Hans Pedersen Co-Founder | Seed | — | — |
| 14 | PlatoScience Provider of a plug and play neurostimulation headset | $609K | 86 mo ago | 5 | Morten Friis-Olivarius Co-Founder | Seed | — | — |
| 15 | Obital Provider of eye tracking software for disabled individuals | $383K | 91 mo ago | 5 | Frederik Ostergaard Neble Founder & CEO | Seed | — | — |
| 16 | Nordic NeuroSTIM Developer of reflex-based electrical therapy to improve the outcome of gait training for stroke patients | $112K | 75 mo ago | 5 | Christian Christiansen CEO | Seed | 12 patents Gait training and detection using electrically stimulated footwear for rehabilitation | — |
Top 12 Neurology companies in Denmark
#1
Series A · Copenhagen, Capital Region of Denmark · founded 2020 · 3 employees$20.8Mraised▾
Developer of RNA therapeutics for the treatment of neurological disorders. The company is pioneering the development of brain-selective RNA medicines for neurological diseases mainly focused on Epilepsy and Parkinson’s Disease.
- Jan 2025Series A$20.8M
- Seed—
#2
Series B · Aarhus, Capital Region of Denmark · founded 2015 · 26 employees$174.3Mraised▾
NMD Pharma is developing small molecule drugs for neuromuscular disorders including myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy (SMA). It is currently developing compounds that can maximize the residual muscle activity by targeting an ion channel specific to skeletal muscle fibers.
- Nov 2023Series B$80.8M
- Feb 2022Series B$39.6M
- Mar 2018Series A$47M
- Jun 2016Seed$6.9M
#3
Series A · Copenhagen, Capital Region of Denmark · founded 2016 · 3 employees$27Mraised▾
Developer of therapeutics for the treatment of neuropathic pain and hearing disorders. The company's lead candidates HB-086 and HB-097 are therapeutic proteins for peripheral neuropathic pain and sensorial hearing loss.
- Dec 2023Series A$24.7M
- Jun 2022Grant (prize money)$2.5M
- 2021Grant (prize money)$61.3K
- Apr 2018Seed$264.8K
#4
Series B · Copenhagen, Capital Region of Denmark · founded 2020 · 16 employees$102.1Mraised▾
Developer of small-molecule therapeutics for neurodegenerative diseases. The company is focused on restoring neuron function, resolving neuroinflammation, microglia function in patients with Alzheimer’s and other neurodegenerative disorders. The drug discovery platform targets structural approaches, AI-driven computational chemistry, and cell-based screening.
- Oct 2022Grant (prize money)$4.9M
- Jun 2022Series B$23.5M
- Jul 2021Series A$73M
- Jun 2020Series A$5.5M
#5
Public · Vaerlose, Capital Region of Denmark · founded 1995 · 1 employees$70.9Mraised▾
Developer of therapeutics for pain management. The company is also developing a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles.
#6
Funding Raised · Copenhagen, Capital Region of Denmark · founded 2013 · 1 employees$873Kraised▾
Developer of small molecule therapies to treat various diseases. The company is developing a pipeline of first-in-class small molecule Vps10p modulators for various therapy areas and indications. The company's lead candidate include VES001 for Frontotemporal Dementia and eye diseases.
- Jan 2024Grant (prize money)$873K
#7
Funding Raised · Aarhus, Capital Region of Denmark · founded 2009$1.6Mraised▾
Provider of a medical device for the treatment of migraine. The company offers Rehaler medical device is a drug-free inhaler based on accurately adjusted partial rebreathing, used during the aura phase of a migraine.
- 2023Grant (prize money)$1.6M
#8
Seed · Kongens Lyngby, Capital Region of Denmark · founded 2018 · 10 employees$2.6Mraised▾
Provider of solutions for treating and diagnosing neurological disease. It uses gamma stimulation therapy and digital biomarkers. The company is developing new lighting technology, based on gamma light therapy, in which the light is non-perceptible and thus is not gives a problem to vision or causing discomfort, while continuously gathering data for diagnostic.
#9
Early Stage · Frederiksberg, Capital Region of Denmark · founded 2000 · 1 employees$3.4Mraised▾
Developer of a medical device for the treatment of neurological diseases. The Re5-NTS system uses pulsed electric fields and a patented Re5 applicator transmits electromagnetic pulses to the brain which activate the secretion of growth factors and interleukins from capillaries and neurons that causes angiogenesis and enhanced brain plasticity. Also, can be used for the treatment of osteoarthritis.
- Jan 2011Unattributed$896K
- Jan 2010Unattributed$966.7K
- Feb 2009Unattributed$1.2M
- Jun 2007Unattributed$182.3K
#10
Deadpooled · Ballerup, Capital Region of Denmark · founded 1999$5.1Mraised▾
Drug delivery systems and therapeutics for CNS diseases.
#11
Acquired · Horsholm, Hovedstaden · founded 2010 · 13 employees$2.5Mraised▾
Developer of new innovative drugs for the treatment of movement disorders. The lead candidate JM-010, a fixed-dose combination of 2 safe marketed products in a proprietary formulation for the treatment of L-DOPA-induced dyskinesia (LID) in Parkinson’s disease (PD). Its mechanism combines serotonergic receptor agonists and is currently in phase 2a/PoC study.
- Jul 2019Series A$2.5M
- Jun 2012Series A—
- May 2011Seed—
#12
Seed · Copenhagen, Capital Region of Denmark · founded 2012 · 2 employees$1.6Mraised▾
Developer of neuroprotectants for multiple Indications. The company is developing novel inhibitors of PDZ domain proteins to target unmet medical needs. The lead candidate AVLX-144 is a dimeric peptide-like drug candidate for the treatment of subarachnoid hemorrhage and acute ischemic stroke, which targets the intracellular scaffolding protein, postsynaptic density protein 95 (PSD-95).
- Jun 2015Grant (prize money)$2.7M
- Apr 2015Seed$1.6M
- Apr 2013Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Neuroscience & Neurotech is moving in Denmark
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 191 Denmark-affiliated papers.
- Aarhus University62
- Aalborg University43
- Aarhus University Hospital35
- University of Copenhagen26
- Bispebjerg Hospital19
- Deep brain stimulation4→8
- Subthalamic nucleus1→5
- Brain stimulation1→5
- Stimulation1→5
- Neuromodulation1→9
- Deep brain stimulation17→20
- Neurostimulation4→7
- Resting state fMRI1→4
- Deep brain stimulation21
- Parkinson's disease13
- Stimulation6
- Disease6
- Dystonia4
Where neurotech is researched across Denmark
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.